Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Scientific Reports|September 17, 2016
Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein ResponseDadi Jiang, Connor Lynch, Bruno C Medeiros, et al.
Blood Advances|January 4, 2018
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyDaniel J DeAngelo, Wendy Stock, Anthony S Stein, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
American Journal of Hematology|January 10, 2019
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicinElias Jabbour, Anjali S Advani, Matthias Stelljes, et al.
Leukemia & Lymphoma|July 12, 2017
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete responseCaner Saygin, Nikolaos Papadantonakis, Ryan D Cassaday, et al.
Haematologica|April 17, 2025
Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort studyShagun Singh, Supriya Peshin, Betsy C Wertheim, et al.
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
Cancer|November 24, 2020
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemiaWendy Stock, Giovanni Martinelli, Matthias Stelljes, et al.
Blood Cancer Journal|January 12, 2021
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosisVikram J Premkumar, Suzanne Lentzsch, Samuel Pan, et al.
Nature Medicine|January 23, 2023
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim resultsSham Mailankody, Jeffrey V Matous, Saurabh Chhabra, et al.
Pageof 11